EMBLEM Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) high voltage (HV) Capacitor
BOSTON SCIENTIFIC CORPORATION · Decision date Oct 2, 2026
What did the FDA decide?
FDA recorded a 30-day notice decision, OK30, dated 2026-10-02 for P110042/S216, a supplement to Boston Scientific Corporation's EMBLEM Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) high voltage (HV) Capacitor. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier. The recorded statement describes adjusting manufacturing steps and modifying laser equipment software for the HV capacitors in EMBLEM S-ICD devices.
This action concerns the capacitor component and its fabrication process rather than a new approval of the complete S-ICD system. The device category is implantable cardioverter defibrillator (non-CRT), specialty cardiovascular, product code LWS. The source record includes no documents, so the specific process parameters, software changes and any supporting data are not available here; clinical or legal implications of the change cannot be assessed from these fields alone.
FDA approval order statement
to adjust the manufacturing steps and modify the laser equipment software for the HV capacitors in EMBLEM SICD devices
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P110042/S216
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- LWS
- Decision code
- OK30
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Boston Scientific Corporation
- Product code
- LWS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P110042. Subsequent supplements may change the device or its indications.
FDA decision timeline
P110042 · Original PMA
SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM
P110042/S216 received
Application receipt date recorded by FDA.
P110042/S216 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P110042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | PMA approval | Sep 28, 2012 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P110042/S216
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


